Raju Prasad

Dr. Prasad has served as the Chief Financial Officer since March 2023. Prior to joining the company, Dr. Prasad served in various roles at William Blair & Company since March 2014, most recently as a Partner. While at William Blair he was a senior biotechnology analyst covering small-cap, mid-cap, and large-cap companies. He led the firms’ initiative on launching coverage in the areas of cell therapy, gene therapy, and gene editing. Dr. Prasad previously worked as a research associate with the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. He also serves on the advisory board of Portal Innovations, a life sciences venture development engine. Dr. Prasad has a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus on genetic toxicology and mutagenesis. He has authored several publications in scientific journals and is the author of Building Breakthroughs: On the Frontier of Medical Innovation.